Are sperm parameters able to predict the success of assisted reproductive technology? A retrospective analysis of over 22,000 assisted reproductive technology cycles.


Journal

Andrology
ISSN: 2047-2927
Titre abrégé: Andrology
Pays: England
ID NLM: 101585129

Informations de publication

Date de publication:
02 2022
Historique:
revised: 26 10 2021
received: 20 08 2021
accepted: 27 10 2021
pubmed: 2 11 2021
medline: 9 3 2022
entrez: 1 11 2021
Statut: ppublish

Résumé

An explosive increase in couples attending assisted reproductive technology has been recently observed, despite an overall success rate of about 20%-30%. Considering the assisted reproductive technology-related economic and psycho-social costs, the improvement of these percentages is extremely relevant. However, in the identification of predictive markers of assisted reproductive technology success, male parameters are largely underestimated so far. Retrospective, observational study. To evaluate whether conventional semen parameters could predict assisted reproductive technology success. All couples attending a single third-level fertility center from 1992 to 2020 were retrospectively enrolled, collecting all semen and assisted reproductive technology parameters of fresh cycles. Fertilization rate was the primary end-point, representing a parameter immediately dependent on male contribution. Pregnancy and live birth rates were considered in relation to semen variables. Statistical analyses were performed using the parameters obtained according to the World Health Organization manual editions used for semen analysis. Note that, 22,013 in vitro fertilization and intracytoplasmic sperm injection cycles were considered. Overall, fertilization rate was significantly lower in patients with abnormal semen parameters compared to normozoospermic men, irrespective of the World Health Organization manual edition. In the in vitro fertilization setting, both progressive motility (p = 0.012) and motility after capacitation (p = 0.002) significantly predicted the fertilization rate (statistical accuracy = 71.1%). Sperm motilities also predicted pregnancy (p < 0.001) and live birth (p = 0.001) rates. In intracytoplasmic sperm injection cycles, sperm morphology predicted fertilization rate (p = 0.001, statistical accuracy = 90.3%). Sperm morphology significantly predicted both pregnancy (p < 0.001) and live birth (p < 0.001) rates and a cut-off of 5.5% was identified as a threshold to predict clinical pregnancy (area under the curve = 0.811, p < 0.001). Interestingly, sperm motility plays a role in predicting in vitro fertilization success, while sperm morphology is the relevant parameter in intracytoplasmic sperm injection cycles. These parameters may be considered reliable tools to measure the male role on ART outcomes, potentially impacting the clinical management of infertile couples.

Sections du résumé

BACKGROUND
An explosive increase in couples attending assisted reproductive technology has been recently observed, despite an overall success rate of about 20%-30%. Considering the assisted reproductive technology-related economic and psycho-social costs, the improvement of these percentages is extremely relevant. However, in the identification of predictive markers of assisted reproductive technology success, male parameters are largely underestimated so far.
STUDY DESIGN
Retrospective, observational study.
OBJECTIVES
To evaluate whether conventional semen parameters could predict assisted reproductive technology success.
MATERIALS AND METHODS
All couples attending a single third-level fertility center from 1992 to 2020 were retrospectively enrolled, collecting all semen and assisted reproductive technology parameters of fresh cycles. Fertilization rate was the primary end-point, representing a parameter immediately dependent on male contribution. Pregnancy and live birth rates were considered in relation to semen variables. Statistical analyses were performed using the parameters obtained according to the World Health Organization manual editions used for semen analysis.
RESULTS
Note that, 22,013 in vitro fertilization and intracytoplasmic sperm injection cycles were considered. Overall, fertilization rate was significantly lower in patients with abnormal semen parameters compared to normozoospermic men, irrespective of the World Health Organization manual edition. In the in vitro fertilization setting, both progressive motility (p = 0.012) and motility after capacitation (p = 0.002) significantly predicted the fertilization rate (statistical accuracy = 71.1%). Sperm motilities also predicted pregnancy (p < 0.001) and live birth (p = 0.001) rates. In intracytoplasmic sperm injection cycles, sperm morphology predicted fertilization rate (p = 0.001, statistical accuracy = 90.3%). Sperm morphology significantly predicted both pregnancy (p < 0.001) and live birth (p < 0.001) rates and a cut-off of 5.5% was identified as a threshold to predict clinical pregnancy (area under the curve = 0.811, p < 0.001).
DISCUSSION
Interestingly, sperm motility plays a role in predicting in vitro fertilization success, while sperm morphology is the relevant parameter in intracytoplasmic sperm injection cycles. These parameters may be considered reliable tools to measure the male role on ART outcomes, potentially impacting the clinical management of infertile couples.

Identifiants

pubmed: 34723422
doi: 10.1111/andr.13123
pmc: PMC9298690
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

310-321

Informations de copyright

© 2021 The Authors. Andrology published by Wiley Periodicals LLC on behalf of American Society of Andrology and European Academy of Andrology.

Références

Hum Fertil (Camb). 2013 Sep;16(3):175-93
pubmed: 23862664
Lancet. 2001 Jun 30;357(9274):2075-9
pubmed: 11445099
J Urol. 2012 Feb;187(2):602-6
pubmed: 22177177
Semin Reprod Med. 2020 Jan;38(1):36-47
pubmed: 33152769
Fertil Steril. 1995 Jan;63(1):87-91
pubmed: 7805929
Fertil Steril. 2015 Jan;103(1):53-8
pubmed: 25450299
Reprod Biomed Online. 2006 Jul;13(1):65-70
pubmed: 16820111
Hum Reprod. 2011 Dec;26(12):3207-12
pubmed: 21965314
JAMA. 2013 Jul 3;310(1):75-84
pubmed: 23821091
Fertil Steril. 2019 Apr;111(4):708-713
pubmed: 30929730
Fertil Steril. 1998 Aug;70(2):305-14
pubmed: 9696226
Semin Reprod Med. 2021 Nov;39(5-06):200-206
pubmed: 34256413
Fertil Steril. 2012 Dec;98(6):1395-9
pubmed: 22981171
Reprod Biomed Online. 2010 Jan;20(1):2-10
pubmed: 20158983
Asian J Androl. 2010 Jan;12(1):47-58
pubmed: 20111081
Hum Reprod. 1993 Jul;8(7):1061-6
pubmed: 8408487
Fertil Steril. 2017 Sep;108(3):393-406
pubmed: 28760517
Hum Reprod. 2000 Jun;15(6):1278-83
pubmed: 10831555
Hum Reprod. 2015 Feb;30(2):454-65
pubmed: 25518976
Fertil Steril. 2016 Jun;105(6):1462-8
pubmed: 26930619
Reprod Biomed Online. 2018 Mar;36(3):327-339
pubmed: 29336995
J Androl. 2007 Jan-Feb;28(1):1-4
pubmed: 16957135
Fertil Steril. 2021 Apr;115(4):930-939
pubmed: 33461755
Hum Reprod. 2008 Jul;23(7):1545-52
pubmed: 18385126
Reprod Sci. 2022 Jan;29(1):7-25
pubmed: 33289064
Ann Hum Genet. 1978 Jan;41(3):289-98
pubmed: 147046
Fertil Steril. 1996 Feb;65(2):258-61
pubmed: 8566244
Andrology. 2020 Nov;8(6):1867-1874
pubmed: 32761795
World J Mens Health. 2022 Jul;40(3):347-360
pubmed: 34169687
J Androl. 2004 Jul-Aug;25(4):635-44
pubmed: 15223853
Philos Trans R Soc Lond B Biol Sci. 2013 Jan 5;368(1609):20120353
pubmed: 23166403
Fertil Steril. 2008 Apr;89(4):854-9
pubmed: 17681340
Reprod Biomed Online. 2018 Sep;37(3):315-326
pubmed: 30314886
Mol Reprod Dev. 2001 Sep;60(1):89-96
pubmed: 11550272
Acta Obstet Gynecol Scand. 2006;85(2):236-40
pubmed: 16532921
Hum Reprod. 2009 Nov;24(11):2683-7
pubmed: 19801627
Eur J Hum Genet. 2009 Jan;17(1):1-2
pubmed: 18941473
Urology. 2009 Oct;74(4):789-93
pubmed: 19643462
Fertil Steril. 2011 Mar 1;95(3):1141-5
pubmed: 21030014
Andrology. 2017 Jul;5(4):695-703
pubmed: 28718528
Int J Androl. 1995 Dec;18 Suppl 2:81-7
pubmed: 8719866
Hum Reprod Open. 2019 Mar 27;2019(2):hoz006
pubmed: 30937394
Andrology. 2022 Feb;10(2):310-321
pubmed: 34723422
Schizophr Res. 2011 May;128(1-3):143-9
pubmed: 21353765
Hum Reprod. 2017 Sep 1;32(9):1786-1801
pubmed: 29117321
J Assist Reprod Genet. 2021 Apr;38(4):979-986
pubmed: 33532883
Reprod Biol Endocrinol. 2010 Jun 25;8:77
pubmed: 20579351
J Androl. 1991 Jul-Aug;12(4):231-9
pubmed: 1917688
Fertil Steril. 1994 Oct;62(4):781-5
pubmed: 7926087
Hum Reprod. 2016 Jul;31(7):1588-609
pubmed: 27207175
J Androl. 2005 Sep-Oct;26(5):619-23
pubmed: 16088039
Fertil Steril. 2013 Nov;100(5):1381-8
pubmed: 23876534
Basic Clin Androl. 2018 Apr 02;28:4
pubmed: 29619224
Lancet. 1992 Jul 4;340(8810):17-8
pubmed: 1351601
Reprod Biomed Online. 2014 Mar;28(3):300-9
pubmed: 24456701
J Androl. 2011 Jul-Aug;32(4):356-63
pubmed: 21088229
J Proteome Res. 2009 Jul;8(7):3377-89
pubmed: 19408963
Fertil Steril. 2020 Nov;114(5):914-920
pubmed: 33160513
J Assist Reprod Genet. 2020 Dec;37(12):2929-2945
pubmed: 33073301
Asian J Androl. 2021 Jul-Aug;23(4):421-428
pubmed: 33533739
Acta Eur Fertil. 1991 Nov-Dec;22(6):321-4
pubmed: 1844193
Reprod Biol Endocrinol. 2013 Aug 31;11:84
pubmed: 24004836
Fertil Steril. 2008 Apr;89(4):823-31
pubmed: 17644094
Fertil Steril. 2021 Feb;115(2):290-295
pubmed: 33358019
BJOG. 2017 Sep;124(10):1537-1544
pubmed: 27748040
J Perinat Med. 2009;37(1):43-7
pubmed: 18759685
Reprod Biomed Online. 2006 Apr;12(4):466-72
pubmed: 16740220
JBRA Assist Reprod. 2017 Dec 01;21(4):343-350
pubmed: 29116706

Auteurs

Maria Teresa Villani (MT)

Department of Obstetrics and Gynaecology, Fertility Centre, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Daria Morini (D)

Department of Obstetrics and Gynaecology, Fertility Centre, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Giorgia Spaggiari (G)

Department of Medical Specialties, Unit of Endocrinology, Ospedale Civile of Baggiovara, Azienda Ospedaliero-Universitaria of Modena, Modena, Italy.

Angela Immacolata Falbo (AI)

Department of Obstetrics and Gynaecology, Fertility Centre, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Beatrice Melli (B)

Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy.

Giovanni Battista La Sala (GB)

Department of Obstetrics and Gynaecology, Fertility Centre, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Marilina Romeo (M)

Department of Medical Specialties, Unit of Endocrinology, Ospedale Civile of Baggiovara, Azienda Ospedaliero-Universitaria of Modena, Modena, Italy.
Department of Biomedical, Metabolic and Neural Sciences, Unit of Endocrinology, University of Modena and Reggio Emilia, Modena, Italy.

Manuela Simoni (M)

Department of Medical Specialties, Unit of Endocrinology, Ospedale Civile of Baggiovara, Azienda Ospedaliero-Universitaria of Modena, Modena, Italy.
Department of Biomedical, Metabolic and Neural Sciences, Unit of Endocrinology, University of Modena and Reggio Emilia, Modena, Italy.

Lorenzo Aguzzoli (L)

Department of Obstetrics and Gynaecology, Fertility Centre, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Daniele Santi (D)

Department of Medical Specialties, Unit of Endocrinology, Ospedale Civile of Baggiovara, Azienda Ospedaliero-Universitaria of Modena, Modena, Italy.
Department of Biomedical, Metabolic and Neural Sciences, Unit of Endocrinology, University of Modena and Reggio Emilia, Modena, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH